Esperion Therapeutics, Inc. (NASDAQ:ESPR) had its target price upped by investment analysts at Needham & Company LLC from $58.00 to $72.00 in a research report issued to clients and investors on Tuesday, The Fly reports. The firm presently has a “positive” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s price target suggests a potential upside of 59.40% from the stock’s current price.

A number of other analysts have also recently weighed in on ESPR. Zacks Investment Research cut shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, May 1st. ValuEngine upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Deutsche Bank AG started coverage on shares of Esperion Therapeutics in a report on Friday, June 23rd. They set a “buy” rating and a $48.00 target price for the company. Finally, BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, June 25th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $39.16.

Shares of Esperion Therapeutics (ESPR) traded up 26.39% on Tuesday, hitting $57.09. The company had a trading volume of 2,891,225 shares. The company has a 50-day moving average of $44.47 and a 200 day moving average of $33.65. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $57.15. The stock’s market cap is $1.29 billion.

ILLEGAL ACTIVITY WARNING: “Needham & Company LLC Increases Esperion Therapeutics, Inc. (NASDAQ:ESPR) Price Target to $72.00” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/needham-company-llc-increases-esperion-therapeutics-inc-nasdaqespr-price-target-to-72-00.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Neuberger Berman Group LLC purchased a new position in shares of Esperion Therapeutics during the second quarter valued at approximately $764,000. Bank of New York Mellon Corp raised its stake in Esperion Therapeutics by 9.8% in the second quarter. Bank of New York Mellon Corp now owns 114,853 shares of the biopharmaceutical company’s stock valued at $5,315,000 after buying an additional 10,250 shares in the last quarter. SG Americas Securities LLC raised its stake in Esperion Therapeutics by 74.5% in the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 2,991 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in Esperion Therapeutics during the second quarter valued at about $509,000. Finally, Schwab Charles Investment Management Inc. raised its stake in Esperion Therapeutics by 23.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 68,275 shares of the biopharmaceutical company’s stock valued at $3,160,000 after buying an additional 13,146 shares in the last quarter. Institutional investors and hedge funds own 85.20% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

The Fly

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.